What Researchers Did
This study investigated how combining Enhanced External Counterpulsation (EECP) and Hyperbaric Oxygen Therapy (HBOT) affects heart function and patient outcomes in 100 adults with ischemic cardiomyopathy.
What They Found
The study found significant improvements in heart function, with left ventricular ejection fraction (LVEF) increasing from 34.17% to 41.43% (p<0.001). Patients also showed better exercise capacity, with a 6-minute walk test distance increasing from 243.7 meters to 367.4 meters (p<0.001), and their heart failure symptoms (NYHA class) improved from severe to mainly mild (p<0.001). Other markers like global longitudinal strain and NT-proBNP also improved significantly.
What This Means for Canadian Patients
For Canadian patients living with ischemic cardiomyopathy, these interim findings suggest that adding EECP and HBOT to their current medical therapy could potentially enhance heart function and improve their ability to perform daily activities. This combined approach might lead to a better quality of life by reducing symptoms and the need for hospitalizations related to heart failure.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
A key limitation is that these are interim results from an ongoing study, meaning the long-term benefits and safety of this combined therapy are still being evaluated.